Australia markets closed

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
44.80+1.60 (+3.70%)
As of 10:45AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.59B
Enterprise value 3.06B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.32
Price/book (mrq)13.04
Enterprise value/revenue 7.04
Enterprise value/EBITDA -5.92

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-8.51%
S&P500 52-week change 322.43%
52-week high 354.98
52-week low 331.52
50-day moving average 347.43
200-day moving average 342.11

Share statistics

Avg vol (3-month) 3717.46k
Avg vol (10-day) 3745.2k
Shares outstanding 583.13M
Implied shares outstanding 683.13M
Float 872.27M
% held by insiders 14.02%
% held by institutions 1100.15%
Shares short (15 Apr 2024) 44.38M
Short ratio (15 Apr 2024) 46.09
Short % of float (15 Apr 2024) 46.15%
Short % of shares outstanding (15 Apr 2024) 45.27%
Shares short (prior month 15 Mar 2024) 43.78M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -138.58%
Operating margin (ttm)-151.93%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)442.59M
Revenue per share (ttm)5.75
Quarterly revenue growth (yoy)8.30%
Gross profit (ttm)N/A
EBITDA -553.18M
Net income avi to common (ttm)-613.35M
Diluted EPS (ttm)-8.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)N/A
Total cash per share (mrq)N/A
Total debt (mrq)N/A
Total debt/equity (mrq)339.39%
Current ratio (mrq)N/A
Book value per share (mrq)3.35

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A